Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1991-03-04
1994-07-12
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
530402, 530399, 530350, 5303873, 536 234, 435 697, C07K 1300, C07K 1504, A61K 3702
Patent
active
053289846
ABSTRACT:
Proteins that are impermeable and foreign to the eukaryotic cells can now be delivered across cellular membranes into the cytosol of target cells by making a chimeric protein having specific attributes. A method of making such chimeric proteins is disclosed. As an example, a chimeric protein PE-Bar with dual enzymatic activity has been made. The chimeric proteins can be used for cytotoxic, diagnostic or therapeutic purposes, such as for compensating the deficiency or defect of an enzyme or a protein which may be causative of a disease or an abnormality.
REFERENCES:
patent: 4675382 (1987-06-01), Murphy
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4933288 (1990-06-01), Greenfield
patent: 5080898 (1992-01-01), Murphy
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5084556 (1992-01-01), Brown
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5206353 (1993-04-01), Berger et al.
Lorberbaum-Galski et al., "Interleukin 2 (IL 2) PE40 is Cytotoxic . . . ", J. Biol. Chem. 263:18650-18656, Dec. 15, 1988.
Hartley, "Barnase and Barstar", J. Mol. Biol. 202:913-915, 1988.
Kondo et al., "Activity of Immunotoxins Constructed with Modified Pseudomonas Exotoxin A . . . ", J. Biol. Chem. 263:9470-9475, Jul. 5, 1988.
Batra et al., "Anti-Tac (Fv)-PE40, a Single Chain Antibody Pseudomonas Fusion Protein . . . ", J. Biol. Chem. 265:15198-15202, Sep. 5, 1990.
Roberge et al., "Selective Immunosuppression of Activated T Cells . . . ", J. Immunol. 143:3498-3502, Dec. 1, 1989.
Prior et al, "Cytotoxic Activity of a Recombinant Fusion Protein . . . ", Cancer Res. 51:174-180, Jan. 1, 1991.
Debinski et al., "Substitution of Foreign Protein Sequences into a Chimeric Toxin . . . ", Mol. Cell. Biol. 11:1751-1753, Mar. 1991.
Siegall et al., "Cytotoxic Activity of an Interleukin 6-Pseudomonas exotoxin fusion protein . . . ", PNAS 85:9738-9742, Dec. 1988.
Debinski Waldemar
Fitzgerald David J.
Pastan Ira H.
Siegall Clay
Trevor Prior
The United States as represented by the Department of Health & H
Walsh Stephen
Wax Robert A.
LandOfFree
Recombinant chimeric proteins deliverable across cellular membra does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant chimeric proteins deliverable across cellular membra, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant chimeric proteins deliverable across cellular membra will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-397266